Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women

摘要: Data from the Danish cohort (n = 67) of a multicenter trial oral alendronate in prevention postmenopausal osteoporosis were used to evaluate capacity biochemical markers predict changes bone mineral density (BMD). A panel measured: serum N-terminal midfragment osteocalcin (N-MID OC); total (total bone-specific alkaline phosphatase (BSAP); and urine C-telopeptides type I collagen (sCL uCL); N-telopeptide crosslinks (NTX); deoxypyridinoline (dPyr). The correlation between change baseline at months 3-12 OC, N-MID sCL, uCL, NTX 2 year response spine BMD ranged r -0.45 -0.78 (p < 0.001), -0.38 0.10 (n.s. p 0.002) for BSAP dPyr. Sensitivity specificity assess accuracy month 6 predicting loss over years. cutpoints 30% OC) or 50% (all other markers) decrease baseline. levels 82% OC), 98% 78% NTX), 89% (uCL). Specificities 91% 59% 100% (sCL), 71% (uCL), 84% (NTX). Positive predictive values 95% 87% 90% In comparison, capacities hip similar: sensitivity, 82%; specificity, 55%; positive value, 79%. conclusion, short-term valid predictors long-term BMD. Short-term sensitive revealed similar densitometry measured offered fast alternative monitoring treatment.